Benzinga · Aug 10, 2026
B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $1.5
B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $2 to $1.5.
NASDAQ · BTMD
biote Corp.
Healthcare · Medical - Care Facilities
$1.12
Up+$0.02 (+1.79%)
Updated Oct 6, 2026, 9:41 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 136.76M
- P/E ratio
- 3.11
- Dividend yield
- 0.00%
- 52-week range
- $1.10 – $3.26
- Volume
- 205.2K
- Avg. volume
- 121.8K
Price performance · BTMD
BTMD price history
1M range · 0 trading sessions · Daily adjusted prices
BTMD does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BTMD news
The latest Smart Investors Daily articles mentioning BTMD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BTMD research
Overview
Company profile and research snapshot.
Company profile
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $8.62
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | B. Riley Securities | Neutral | — |
| Aug 7, 2026 | TD Cowen | Buy | — |
| Apr 16, 2026 | Truist Securities | Buy | — |
| Mar 12, 2026 | TD Cowen | Buy | — |
| Mar 12, 2026 | B. Riley Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
TD Cowen Maintains Buy on Biote, Lowers Price Target to $2
TD Cowen analyst Jonna Kim maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $2.5 to $2.
Yahoo · Aug 6, 2026
Biote Corp (BTMD) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges and ...
Despite a 9.5% revenue decline and revised guidance, Biote Corp (BTMD) focuses on operational recovery, supply normalization, and inorganic growth opportunities.
SeekingAlpha · Aug 6, 2026
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
biote Corp. (BTMD) Q2 2026 Earnings Call August 5, 2026 5:00 PM EDTCompany ParticipantsRobert Peterson - Interim CEO, CFO & Chief Business...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
